Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH

Posted on by Steatosite

Joint studies will evaluate one or more of Pfizer’s investigational NASH therapies in combination with Novartis’s FXR agonist for the treatment of the progressive liver disease

https://www.businesswire.com/news/home/20181028005011/en/Pfizer-Announces-Clinical-Development-Agreement-Novartis-Advan

Published by

Steatosite

The creation of the NASH Data Commons will provide a unified data system that promotes sharing of genomic and clinical data, forming the basis for a comprehensive knowledge system that centralises, standardises and makes accessible data. These datasets will lead to a much deeper understanding of which therapies are most effective for individual patients. With each new dataset added e.g. additional ‘omics’ data, it will evolve into a smarter, more comprehensive knowledge system that will foster important discoveries in chronic liver disease and increase the success of treatments for patients.

Leave a Reply

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out /  Change )

Google photo

You are commenting using your Google account. ( Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. ( Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out /  Change )

Cancel

Connecting to %s